Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited Telix is a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic oncology products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing pharmacovigilance@telixpharma.com. Please see full Illuccix Prescribing Information:https://illuccixhcp.com/wp-content/uploads/illuccix-prescribing-information.pdf

Results from the ZIRCON-X study show that almost half of all patients imaged with Telix’s kidney cancer imaging candidat...
19/11/2025

Results from the ZIRCON-X study show that almost half of all patients imaged with Telix’s kidney cancer imaging candidate, TLX250-CDx (Zircaix®), would have undergone a change in clinical management when compared with baseline standard-of-care imaging.

New analysis found that 48.6% of patients would have experienced a management change, and over 20% of these patients could have potentially avoided invasive biopsy. More than a third of evaluable patients would have undergone a major change, including escalation or de-escalation of treatment.

ZIRCON-X was a non-interventional, prospective, post-hoc study using imaging data from the parent pivotal Phase 3 ZIRCON study to assess the impact of TLX250-CDx PET/CT on decision-making for patients with indeterminate renal masses (IRMs).

The data will be presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO) being held in Phoenix, AZ from December 2 to 5.

Read more on our website: https://bit.ly/3XB7LzB

TLX250-CDx has not received a marketing authorization in any jurisdiction. Brand name subject to final regulatory approval.

12/11/2025

During , we’re celebrating the culture of Quality that underpins everything we do at Telix.

Rujeela, one of our Quality Leads, discusses how Quality is a shared responsibility across every part of the organization - built on collaboration, problem-solving, and a constant focus on patients.

It’s how we continuously improve and deliver safe, reliable, and innovative products that make a difference for patients worldwide.

Do you see yourself at Telix?

Explore open roles and learn more about our culture: https://telixpharma.com/careers

Final results from the Phase 2 OPALESCENCE trial of TLX250-CDx (⁸⁹Zr-girentuximab) in metastatic triple negative breast ...
12/11/2025

Final results from the Phase 2 OPALESCENCE trial of TLX250-CDx (⁸⁹Zr-girentuximab) in metastatic triple negative breast cancer (mTNBC) have been published in the European Journal of Nuclear Medicine and Molecular Imaging.

The investigator-initiated trial - conducted at ICO in France under the supervision of Dr. Caroline Rousseau - evaluated the safety and diagnostic utility of Telix’s CAIX-targeting PET imaging candidate in this aggressive breast cancer subtype, as proof of concept for therapy.

Authors conclude that TLX250-CDx “is a sensitive imaging method and offers promise for novel theranostics for mTNBC patients”.

These findings build on a growing body of evidence supporting the expansion of Telix’s CAIX-targeting theranostic programs into new indications beyond kidney cancer.

Read more on our website: https://bit.ly/43s7VwJ

TLX250-CDx has not received a marketing authorization in any jurisdiction.

Today, on Veterans Day, we honor the courage, sacrifice, and service of all Veterans.As we pause to recognize their dedi...
11/11/2025

Today, on Veterans Day, we honor the courage, sacrifice, and service of all Veterans.

As we pause to recognize their dedication, we are reminded of the importance of supporting their ongoing health and wellbeing. Prostate cancer affects Veterans at higher rates, and awareness, early detection, and access to care can make a life-changing difference.

We also acknowledge the incredible Veterans working at Telix. Their dedication to our mission and improving patient outcomes is a testament to the strength and commitment shown by Veterans everywhere.

Thank you to all who have served, and to those who continue to serve🎗️

For prostate cancer resources for Veterans, see here: https://zerocancer.org/help-and-support/resources-for/veterans

Join Telix at two upcoming investor conferences to learn more about the company’s growth strategy, commercial progress, ...
05/11/2025

Join Telix at two upcoming investor conferences to learn more about the company’s growth strategy, commercial progress, and theranostic pipeline.

🔵 Kevin Richardson, CEO, Precision Medicine, will join a fireside chat at the UBS Global Healthcare Conference.

🔵 Richard Valeix, CEO, Therapeutics, will take part in a fireside chat at the Jefferies Global Healthcare Conference.

Both sessions will be webcast live and available on demand.

For details and registration, visit: ir.telixpharma.com/events-presentations

A new home for Telix clinical trials.Finding the right trial can often be complex. Telix’s new Clinical Trials page is d...
30/10/2025

A new home for Telix clinical trials.

Finding the right trial can often be complex. Telix’s new Clinical Trials page is designed to make information about our global theranostic studies easier to find and navigate for patients, carers and the wider community.

With clear summaries, straightforward navigation and regularly updated content, the site supports greater awareness and access to information about our clinical programs.

🔗 Explore the new site: https://clinicaltrials.telixpharma.com

These shoes represent the nearly 2,000 Australians diagnosed with a brain tumor each year.Each pair tells a story of a l...
28/10/2025

These shoes represent the nearly 2,000 Australians diagnosed with a brain tumor each year.

Each pair tells a story of a life changed and a call for greater action.

Today, Telix proudly supports Brain Tumour Alliance Australia’s Head to the Hill event at Parliament House in Canberra, bringing together patients, families, carers and researchers to highlight the impact of brain tumors.

Alongside Hon. Minister Mark Butler, Richard Scolyer AO and Gail O’Brien AO, BTAA Chair Craig Cardinal launched the first Australian Brain Tumour Landscape Report, calling for stronger Government support for brain cancer research, clinical care and patient services.

At Telix, we’re committed to improving outcomes for people with brain cancer. Our theranostic candidates combine targeted radiopharmaceutical therapy with diagnostic imaging to potentially help physicians better see, track and treat disease.

Learn more about our neuro-oncology portfolio: https://telixpharma.com/our-portfolio/disease-areas/brain-cancer/

Read the report: https://btaa.org.au/news/latest-news/new-research-brain-cancers-impact-society

TLX250-CDx (Zircaix®, ⁸⁹Zr-DFO-girentuximab), Telix’s kidney cancer imaging candidate, has been included in latest inter...
23/10/2025

TLX250-CDx (Zircaix®, ⁸⁹Zr-DFO-girentuximab), Telix’s kidney cancer imaging candidate, has been included in latest international guidelines for the molecular imaging of renal masses.

Published on the SNMMI website and in The Journal of Nuclear Medicine, the guidelines recognize the emerging role of molecular imaging in the characterization and management of indeterminate renal lesions.

The expert panel notes that TLX250-CDx PET "appears to be a well-tolerated and accurate method for non-invasive identification of clear cell renal cell carcinoma (ccRCC)", supported by data from Telix's pivotal Phase 3 ZIRCON trial.

Read more on our website here: https://bit.ly/3JsiDwh

The first patient has been dosed in Telix’s SOLACE trial evaluating TLX090 (¹⁵³Sm-DOTMP), a next-generation radiopharmac...
22/10/2025

The first patient has been dosed in Telix’s SOLACE trial evaluating TLX090 (¹⁵³Sm-DOTMP), a next-generation radiopharmaceutical candidate designed to deliver targeted radiation to bone tumors for durable, non-opioid pain relief.

Bone pain affects up to 90% of men with metastatic prostate cancer and 70% of women with metastatic breast cancer, yet many patients remain under-treated or rely on chronic opioid use.

The SOLACE study will assess safety, dosimetry, pharmacokinetics and pain palliation to inform a streamlined development path for this investigational therapy.

Read more on our website here: https://bit.ly/4oDa1lz

TLX090 has not received a marketing authorization in any jurisdiction.

20/10/2025

Up to 1 in 4 men with suspected prostate cancer decline a biopsy, leaving them at risk of misdiagnosis or delayed treatment.

As featured on Channel Nine National News, Telix’s BiPASS™ Phase 3 study is exploring a non-invasive alternative to detect the disease.

Now recruiting at the Australian Prostate Centre in Melbourne, the study will evaluate the use of PSMA-PET in combination with MRI to improve diagnostic accuracy and reduce the need for biopsies.

BiPASS™ builds on a promising body of research, including the PRIMARY studies led by Professor Louise Emmett at St Vincent’s Hospital in Sydney, where the study is opening soon - alongside U.S. sites.

Learn more on our website: https://clinicaltrials.telixpharma.com/trial/bipass/

Telix reports 53% year-over-year revenue growth and raises full-year guidance.Unaudited group revenue for the quarter en...
14/10/2025

Telix reports 53% year-over-year revenue growth and raises full-year guidance.

Unaudited group revenue for the quarter ended 30 September 2025 was approximately US$206 million. Full-year 2025 revenue guidance has been increased to US$800–820 million.

Telix’s therapeutics and precision medicine programs made significant progress this quarter, with Part 2 of the ProstACT Global trial now open and first patients dosed in the Phase 3 BiPASS trial.

With CMS reimbursement now effective for Gozellix®, a growing customer base and the continued European expansion of Illuccix®, Telix enters Q4 in a strong position.

Read the full announcement here: https://bit.ly/4q8SjaV

And the winner of the 2025 EANM Sanjiv Sam Gambhir Award is… Dan Cohen from the Weizmann Institute of Science!Congratula...
08/10/2025

And the winner of the 2025 EANM Sanjiv Sam Gambhir Award is… Dan Cohen from the Weizmann Institute of Science!

Congratulations Dan on your achievement, and best of luck for your visitorship at Stanford University.

A big thank you to the European Association of Nuclear Medicine (EANM) for the opportunity to support the next generation of scientists and physicians through this exciting award, in memory of a pioneer in nuclear medicine and molecular imaging.

Thank you to the brilliant hosts, Joshua James M. & Sophie Veldhuijzen van Zanten and jury members, Burger Irene, Desiree Deandreis, Stefano Fanti & Andrei Iagaru.

Address

55 Flemington Road, North
Melbourne, VIC
3051

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Telix Pharmaceuticals Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Telix Pharmaceuticals Limited:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Telix Pharmaceuticals Limited was established in January 2017. We are a clinical-stage biotechnology company developing a pipeline of molecularly-targeted radiation (MTR) therapies to image and treat cancer. Our team is an experienced group of biopharma clinicians and executives, with a passion for radiation biology and oncology.

In December 2018, Telix acquired ANMI SA, a leader in the field of radiopharmaceutical development. The ANMI team brings a wealth of innovation and experience in the streamlined development and production of novel radiopharmaceuticals. For more information about ANMI, visit anmi.be.

Our products currently focus on unmet needs in cancer care, specifically in:


  • Prostate